Focus: Swedish Orphan Biovitrum (Sobi) is a specialty biotech company headquartered in Waltham, MA, focused on rare diseases, oncology, immunology, and hematology through a portfolio of biologics. The company is publicly traded and operates a mixed model of mature marketed products and early-to-mid stage pipeline programs.
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Stable — net -1 jobs in 30d
28 added, 29 removed. Backfill posture.
Sobi offers rare-disease specialization and commercial growth opportunity, but extreme KINERET dependence and thin pipeline create significant medium-term restructuring risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver (99% of company revenue) but patent expiry approaching with no disclosed LOE date, creating acute business model risk.
Help build intelligence for Swedish Orphan Biovitrum
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Swedish Orphan Biovitrum's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Rare disease niche product; secondary entry on LOE approaching track with minimal revenue contribution.
Minor revenue contributor facing patent erosion; limited franchise value.
Peak-cycle entry with extended exclusivity until Feb 2033; represents long-term rare disease asset.
Specialty oncology supportive care agent; niche indication with approaching patent cliff.
Altuviiio Market Study Highlights How Industry Demand Is Evolving - openPR.com
Altuviiio Market Study Highlights How Industry Demand Is Evolving openPR.com
Respiratory Biologics Market Report 2026 Market Outlook Supported By A Forecast 16.1% CAGR - openPR.com
Respiratory Biologics Market Report 2026 Market Outlook Supported By A Forecast 16.1% CAGR openPR.com
Should FCS Drug Backing Require Action From Sobi (OM:SOBI) Investors? - Simply Wall Street
Should FCS Drug Backing Require Action From Sobi (OM:SOBI) Investors? Simply Wall Street
CVC's cheeky Italian drug buyout will likely work - Breakingviews
CVC's cheeky Italian drug buyout will likely work Breakingviews
Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history - Yahoo Finance UK
Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history Yahoo Finance UK
Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history - Yahoo Finance Singapore
Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history Yahoo Finance Singapore
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.
Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo